• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CYP
Click for more information
6.52% 21.5¢

CYNATA THERAPEUTICS LIMITED - Announcements

Market Cap $34.32M  ! watchlist Created with Sketch. Add to my watchlist

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and... Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
CYP Extension of FUJIFILM Licence Option in GvHD21/03/19
CYP Cleansing Notice21/03/19
CYP Cynata Extends FUJIFILM Licence Option in GvHDPRICE SENSITIVE21/03/19
CYP Appendix 3B-Exercise of Options20/03/19
CYP Trading HaltPRICE SENSITIVE19/03/19
CYP Cleansing Notice13/03/19
CYP Appendix 3B-Exercise of Options13/03/19
CYP Cynata Receives Favourable Advice on Planned CLI TrialPRICE SENSITIVE12/03/19
CYP Joint Study of Cynata MSCs receives VMRAF Funding11/03/19
CYP Positive Pre-Clinical Coronary Artery Disease Data for CYP04/03/19
CYP Appendix 4D & Half-Year Financial StatementsPRICE SENSITIVE27/02/19
CYP Further Cynata Asthma Study Published25/02/19
CYP Cleansing Notice22/02/19
CYP Appendix 3B-Exercise of Options22/02/19
CYP Cleansing Notice18/02/19
CYP Appendix 3B-Exercise of Options18/02/19
CYP Appendix 3Y-Dr John Chiplin11/02/19
CYP Cleansing Notice11/02/19
CYP Appendix 3B-Exercise of Options11/02/19
CYP Study of CYP-001 Published in Leading Peer Review Journal07/02/19
CYP Cleansing Notice04/02/19
CYP Appendix 3B-Exercise of Options04/02/19
CYP December 2018 Quarterly ReportPRICE SENSITIVE29/01/19
CYP Clinical trial results to be presented at major symposium29/01/19
CYP CYP Receives Notice of Acceptance from Aust Patent OfficePRICE SENSITIVE07/01/19
CYP End of Year Newsletter20/12/18
CYP Cynata Completes Clinical Study Report in GvHDPRICE SENSITIVE18/12/18
CYP NHMRC Funding for Osteoarthritis Trial Using Cymerus MSCsPRICE SENSITIVE13/12/18
CYP Cynata Receives $1.3m R&D Tax Incentive RefundPRICE SENSITIVE19/11/18
CYP Replacement-Results of Annual General Meeting15/11/18
CYP Results of Annual General Meeting15/11/18
CYP Chairman's AGM Address15/11/18
CYP Annual General Meeting Presentation15/11/18
CYP CYP Receives Notice of Allowance from European Patent OfficePRICE SENSITIVE07/11/18
CYP Cynata Clinical Trial Data Accepted for presentation at ASH02/11/18
CYP Cyanta Outlook and Investor Presentation01/11/18
CYP Appendix 3Y-Dr Paul Wotton26/10/18
CYP September 2018 Quarterly ReportPRICE SENSITIVE23/10/18
CYP MSCs Demonstrate Anti-Cancer Effects in Pre-Clinical StudiesPRICE SENSITIVE18/10/18
CYP Annual Report to Shareholders11/10/18
CYP Notice of Annual General Meeting/Proxy Form11/10/18
CYP Notification of 2018 Annual General Meeting Date27/09/18
CYP Appendix 3Y-Dr Stewart Washer25/09/18
CYP Appendix 3Y-Dr Ross Macdonald25/09/18
CYP Appendix 3Y-Dr Paul Wotton25/09/18
CYP Cleansing Notice25/09/18
CYP Appendix 3B-Exercise of Options25/09/18
CYP Cynata MSCs Ameliorate CRS in Preclinical StudyPRICE SENSITIVE19/09/18
CYP Results of Meeitng12/09/18
CYP Director Loan Funded Shares-Voluntary Escrow Arrangement05/09/18
CYP Cynata Advances to Official Meeting with Japanese PMDAPRICE SENSITIVE03/09/18
CYP Cynata to Present at Rodman & Renshaw Investor Conference31/08/18
CYP Cynata GvHD Trial Meets all Safety & Efficacy EndpointsPRICE SENSITIVE30/08/18
CYP Updated Appendix 4G24/08/18
CYP Appendix 4G22/08/18
CYP Appendix 4E & Financial StatementsPRICE SENSITIVE22/08/18
CYP Notice of General Meeting/Proxy Form10/08/18
CYP Cymerus MSCs improve cardiac recovery in preclinical studyPRICE SENSITIVE31/07/18
CYP Cleansing Notice16/07/18
CYP Appendix 3B-Exercise of Options16/07/18
CYP Cleansing Notice11/07/18
CYP Appendix 3B-Exercise of Options11/07/18
CYP June 2018 Quarterly ReportPRICE SENSITIVE11/07/18
CYP Cleansing Notice06/07/18
CYP Appendix 3B-Exercise of Options06/07/18
CYP Cynata Enters Development Partnership with RCSIPRICE SENSITIVE02/07/18
CYP Product Development Program Update & Investor PresentationPRICE SENSITIVE26/06/18
CYP Positive 28-day Clinical Trial Data in Cohort BPRICE SENSITIVE21/06/18
CYP Research Collaboration with UNSW for Coronary Artery DiseasePRICE SENSITIVE18/06/18
CYP Positive 6-Month Data from Cohort 1 in Phase 1 Trial in GvHDPRICE SENSITIVE12/06/18
CYP Change in substantial holding07/06/18
CYP Cleansing Notice04/06/18
CYP Appendix 3B04/06/18
CYP Cynata's MSCs Effective in Model of Diabetic WoundsPRICE SENSITIVE31/05/18
CYP $5.2m placement of shares to Fidelity InternationalPRICE SENSITIVE30/05/18
CYP Trading HaltPRICE SENSITIVE28/05/18
CYP Enrolment Completed in Cynata's Phase 1 Clinical TrialPRICE SENSITIVE24/05/18
CYP Cleansing Notice22/05/18
CYP Appendix 3B-Exercise of Options22/05/18
CYP Cleansing Notice15/05/18
CYP Appendix 3B-Exercise of Options15/05/18
CYP Becoming a substantial holder07/05/18
CYP Notice of Allowance from EPO for Patent ApplicationPRICE SENSITIVE07/05/18
CYP March 2018 Quarterly ReportPRICE SENSITIVE27/04/18
CYP Cleansing Notice24/04/18
CYP Appendix 3B-Exercise of Options24/04/18
CYP CYP Completes Patent Application related to CAR-T TherapyPRICE SENSITIVE20/04/18
CYP Cyanta to Present at ARM Investor Day12/04/18
CYP Further US Patent Granted for Cynata Cymerus TechnologyPRICE SENSITIVE11/04/18
CYP Cleansing Notice04/04/18
CYP Appendix 3B-Exercise of Options04/04/18
CYP Cleansing Notice28/03/18
CYP Appendix 3B-Exercise of Options28/03/18
CYP FDA Grants Orphan Drug Designation to Cyanta for CYP-001PRICE SENSITIVE28/03/18
CYP Cleansing Notice13/03/18
CYP Appendix 3B-Exercise of Options13/03/18
CYP Updated Top 20 Shareholders13/03/18
CYP Shaw and Partners Updates Cynata Research Coverage12/03/18
CYP Cleansing Notice28/02/18
CYP Appendix 3B-Exercise of Options28/02/18
CYP Extension of FUJIFILM Licence Option in GvHD
21/03/19
CYP Cleansing Notice
21/03/19
CYP Cynata Extends FUJIFILM Licence Option in GvHD
21/03/19PRICE SENSITIVE
CYP Appendix 3B-Exercise of Options
20/03/19
CYP Trading Halt
19/03/19PRICE SENSITIVE
CYP Cleansing Notice
13/03/19
CYP Appendix 3B-Exercise of Options
13/03/19
CYP Cynata Receives Favourable Advice on Planned CLI Trial
12/03/19PRICE SENSITIVE
CYP Joint Study of Cynata MSCs receives VMRAF Funding
11/03/19
CYP Positive Pre-Clinical Coronary Artery Disease Data for CYP
04/03/19
CYP Appendix 4D & Half-Year Financial Statements
27/02/19PRICE SENSITIVE
CYP Further Cynata Asthma Study Published
25/02/19
CYP Cleansing Notice
22/02/19
CYP Appendix 3B-Exercise of Options
22/02/19
CYP Cleansing Notice
18/02/19
CYP Appendix 3B-Exercise of Options
18/02/19
CYP Appendix 3Y-Dr John Chiplin
11/02/19
CYP Cleansing Notice
11/02/19
CYP Appendix 3B-Exercise of Options
11/02/19
CYP Study of CYP-001 Published in Leading Peer Review Journal
07/02/19
CYP Cleansing Notice
04/02/19
CYP Appendix 3B-Exercise of Options
04/02/19
CYP December 2018 Quarterly Report
29/01/19PRICE SENSITIVE
CYP Clinical trial results to be presented at major symposium
29/01/19
CYP CYP Receives Notice of Acceptance from Aust Patent Office
07/01/19PRICE SENSITIVE
CYP End of Year Newsletter
20/12/18
CYP Cynata Completes Clinical Study Report in GvHD
18/12/18PRICE SENSITIVE
CYP NHMRC Funding for Osteoarthritis Trial Using Cymerus MSCs
13/12/18PRICE SENSITIVE
CYP Cynata Receives $1.3m R&D Tax Incentive Refund
19/11/18PRICE SENSITIVE
CYP Replacement-Results of Annual General Meeting
15/11/18
CYP Results of Annual General Meeting
15/11/18
CYP Chairman's AGM Address
15/11/18
CYP Annual General Meeting Presentation
15/11/18
CYP CYP Receives Notice of Allowance from European Patent Office
07/11/18PRICE SENSITIVE
CYP Cynata Clinical Trial Data Accepted for presentation at ASH
02/11/18
CYP Cyanta Outlook and Investor Presentation
01/11/18
CYP Appendix 3Y-Dr Paul Wotton
26/10/18
CYP September 2018 Quarterly Report
23/10/18PRICE SENSITIVE
CYP MSCs Demonstrate Anti-Cancer Effects in Pre-Clinical Studies
18/10/18PRICE SENSITIVE
CYP Annual Report to Shareholders
11/10/18
CYP Notice of Annual General Meeting/Proxy Form
11/10/18
CYP Notification of 2018 Annual General Meeting Date
27/09/18
CYP Appendix 3Y-Dr Stewart Washer
25/09/18
CYP Appendix 3Y-Dr Ross Macdonald
25/09/18
CYP Appendix 3Y-Dr Paul Wotton
25/09/18
CYP Cleansing Notice
25/09/18
CYP Appendix 3B-Exercise of Options
25/09/18
CYP Cynata MSCs Ameliorate CRS in Preclinical Study
19/09/18PRICE SENSITIVE
CYP Results of Meeitng
12/09/18
CYP Director Loan Funded Shares-Voluntary Escrow Arrangement
05/09/18
CYP Cynata Advances to Official Meeting with Japanese PMDA
03/09/18PRICE SENSITIVE
CYP Cynata to Present at Rodman & Renshaw Investor Conference
31/08/18
CYP Cynata GvHD Trial Meets all Safety & Efficacy Endpoints
30/08/18PRICE SENSITIVE
CYP Updated Appendix 4G
24/08/18
CYP Appendix 4G
22/08/18
CYP Appendix 4E & Financial Statements
22/08/18PRICE SENSITIVE
CYP Notice of General Meeting/Proxy Form
10/08/18
CYP Cymerus MSCs improve cardiac recovery in preclinical study
31/07/18PRICE SENSITIVE
CYP Cleansing Notice
16/07/18
CYP Appendix 3B-Exercise of Options
16/07/18
CYP Cleansing Notice
11/07/18
CYP Appendix 3B-Exercise of Options
11/07/18
CYP June 2018 Quarterly Report
11/07/18PRICE SENSITIVE
CYP Cleansing Notice
06/07/18
CYP Appendix 3B-Exercise of Options
06/07/18
CYP Cynata Enters Development Partnership with RCSI
02/07/18PRICE SENSITIVE
CYP Product Development Program Update & Investor Presentation
26/06/18PRICE SENSITIVE
CYP Positive 28-day Clinical Trial Data in Cohort B
21/06/18PRICE SENSITIVE
CYP Research Collaboration with UNSW for Coronary Artery Disease
18/06/18PRICE SENSITIVE
CYP Positive 6-Month Data from Cohort 1 in Phase 1 Trial in GvHD
12/06/18PRICE SENSITIVE
CYP Change in substantial holding
07/06/18
CYP Cleansing Notice
04/06/18
CYP Appendix 3B
04/06/18
CYP Cynata's MSCs Effective in Model of Diabetic Wounds
31/05/18PRICE SENSITIVE
CYP $5.2m placement of shares to Fidelity International
30/05/18PRICE SENSITIVE
CYP Trading Halt
28/05/18PRICE SENSITIVE
CYP Enrolment Completed in Cynata's Phase 1 Clinical Trial
24/05/18PRICE SENSITIVE
CYP Cleansing Notice
22/05/18
CYP Appendix 3B-Exercise of Options
22/05/18
CYP Cleansing Notice
15/05/18
CYP Appendix 3B-Exercise of Options
15/05/18
CYP Becoming a substantial holder
07/05/18
CYP Notice of Allowance from EPO for Patent Application
07/05/18PRICE SENSITIVE
CYP March 2018 Quarterly Report
27/04/18PRICE SENSITIVE
CYP Cleansing Notice
24/04/18
CYP Appendix 3B-Exercise of Options
24/04/18
CYP CYP Completes Patent Application related to CAR-T Therapy
20/04/18PRICE SENSITIVE
CYP Cyanta to Present at ARM Investor Day
12/04/18
CYP Further US Patent Granted for Cynata Cymerus Technology
11/04/18PRICE SENSITIVE
CYP Cleansing Notice
04/04/18
CYP Appendix 3B-Exercise of Options
04/04/18
CYP Cleansing Notice
28/03/18
CYP Appendix 3B-Exercise of Options
28/03/18
CYP FDA Grants Orphan Drug Designation to Cyanta for CYP-001
28/03/18PRICE SENSITIVE
CYP Cleansing Notice
13/03/18
CYP Appendix 3B-Exercise of Options
13/03/18
CYP Updated Top 20 Shareholders
13/03/18
CYP Shaw and Partners Updates Cynata Research Coverage
12/03/18
CYP Cleansing Notice
28/02/18
CYP Appendix 3B-Exercise of Options
28/02/18
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
21.5¢ 		Change
-0.015(6.52%) 		Mkt cap ! $34.32M
Open High Low Value Volume
22.5¢ 22.5¢ 21.5¢ $15.12K 67.95K

Buyers (Bids)

No. Vol. Price($)
1 20000 22.0¢
 

Sellers (Offers)

Price($) Vol. No.
22.5¢ 100000 1
View Market Depth
Last trade - 13.49pm 03/12/2024 (20 minute delay) ?
Last
22.0¢ 		  Change
-0.015 ( 2.22 %)
Open High Low Volume
22.5¢ 22.5¢ 21.5¢ 33875
Last updated 11.31am 03/12/2024 ?
CYP (ASX) Chart

Top Stories

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
Breaking news: New opportunities for investors & companies - HotCopper opens to capital raising! Companies can now raise capital through HotCopper! It’s a development allowing a highly cost-effective service to ASX-listed companies, while opening new investment opportunities to investors.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.